NO972910L - Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister - Google Patents

Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister

Info

Publication number
NO972910L
NO972910L NO972910A NO972910A NO972910L NO 972910 L NO972910 L NO 972910L NO 972910 A NO972910 A NO 972910A NO 972910 A NO972910 A NO 972910A NO 972910 L NO972910 L NO 972910L
Authority
NO
Norway
Prior art keywords
preparation
methods
receptor antagonists
spiro compounds
5ht1d receptor
Prior art date
Application number
NO972910A
Other languages
English (en)
Norwegian (no)
Other versions
NO972910D0 (no
Inventor
Laramie Mary Gaster
Francis David King
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426029.6A external-priority patent/GB9426029D0/en
Priority claimed from GBGB9512920.1A external-priority patent/GB9512920D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO972910D0 publication Critical patent/NO972910D0/no
Publication of NO972910L publication Critical patent/NO972910L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO972910A 1994-12-22 1997-06-20 Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister NO972910L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426029.6A GB9426029D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9512920.1A GB9512920D0 (en) 1995-06-24 1995-06-24 Novel compounds
PCT/EP1995/004889 WO1996019477A1 (en) 1994-12-22 1995-12-06 Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists

Publications (2)

Publication Number Publication Date
NO972910D0 NO972910D0 (no) 1997-06-20
NO972910L true NO972910L (no) 1997-08-14

Family

ID=26306239

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972910A NO972910L (no) 1994-12-22 1997-06-20 Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister

Country Status (27)

Country Link
US (1) US5972951A (de)
EP (1) EP0799226B1 (de)
JP (1) JPH10510821A (de)
CN (1) CN1175256A (de)
AP (1) AP757A (de)
AR (1) AR002011A1 (de)
AT (1) ATE199085T1 (de)
AU (1) AU697361B2 (de)
BG (1) BG61977B1 (de)
BR (1) BR9510419A (de)
CA (1) CA2208244A1 (de)
CZ (1) CZ192397A3 (de)
DE (1) DE69520075T2 (de)
DZ (1) DZ1957A1 (de)
ES (1) ES2153907T3 (de)
FI (1) FI972583L (de)
HU (1) HUT77650A (de)
IL (1) IL116486A0 (de)
MA (1) MA23753A1 (de)
MX (1) MX9704777A (de)
NO (1) NO972910L (de)
NZ (1) NZ298036A (de)
OA (1) OA10610A (de)
PL (1) PL321048A1 (de)
SK (1) SK80297A3 (de)
TR (1) TR199501597A2 (de)
WO (1) WO1996019477A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519033D0 (en) * 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
GB9522845D0 (en) * 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
EP0861257A1 (de) * 1995-11-08 1998-09-02 Smithkline Beecham Plc Spiro-piperdin derivate als 5ht-receptor antagonisten
EP0862565A1 (de) * 1995-11-22 1998-09-09 Smithkline Beecham Plc Tricyclische spiroverbindungen als 5ht1d-rezeptorantagonisten
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606396D0 (en) * 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761069A1 (fr) * 1997-03-20 1998-09-25 Pf Medicament Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments
CA2347095A1 (en) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
EP1656370B1 (de) * 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Heterocyclische biarylverbindungen und verfahren zu deren herstellung und anwendung
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7700808B2 (en) 2005-12-26 2010-04-20 Nissan Chemical Industries, Ltd. 1-3-bis(substituted phenyl)-3-hydroxypropan-1-one or 2-propen-1-one compound, and salt thereof
WO2008131276A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
US8952175B2 (en) 2007-06-27 2015-02-10 Nissan Chemical Industries, Ltd. Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP4013412B1 (de) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib zur behandlung gastrointestinaler stromakarzinome
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4084779B1 (de) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
US12577211B2 (en) 2020-06-29 2026-03-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69520075T2 (de) 2001-08-02
AU4343396A (en) 1996-07-10
HUT77650A (hu) 1998-07-28
EP0799226A1 (de) 1997-10-08
PL321048A1 (en) 1997-11-24
SK80297A3 (en) 1998-12-02
WO1996019477A1 (en) 1996-06-27
AR002011A1 (es) 1998-01-07
AP9701006A0 (en) 1997-07-31
BG61977B1 (bg) 1998-11-30
AU697361B2 (en) 1998-10-01
TR199501597A2 (tr) 1996-07-21
NZ298036A (en) 1998-11-25
MX9704777A (es) 1997-10-31
EP0799226B1 (de) 2001-02-07
IL116486A0 (en) 1997-08-14
DZ1957A1 (fr) 2002-02-17
CN1175256A (zh) 1998-03-04
FI972583A0 (fi) 1997-06-17
JPH10510821A (ja) 1998-10-20
CZ192397A3 (en) 1997-09-17
CA2208244A1 (en) 1996-06-27
AP757A (en) 1999-09-06
US5972951A (en) 1999-10-26
BR9510419A (pt) 1998-05-19
ES2153907T3 (es) 2001-03-16
FI972583A7 (fi) 1997-08-19
DE69520075D1 (de) 2001-03-15
MA23753A1 (fr) 1996-07-01
ATE199085T1 (de) 2001-02-15
BG101715A (bg) 1998-02-27
FI972583L (fi) 1997-08-19
OA10610A (en) 2002-09-06
NO972910D0 (no) 1997-06-20

Similar Documents

Publication Publication Date Title
NO972910L (no) Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister
NO962543L (no) Cykliske amid-derivater som neurokinin A-antagonister
NO932005L (no) Angiotensin-II-antagonister
NO20062239L (no) Nye tetrahydrospiro[piperidin-2,7'-pyrrolo[3,2-b]pyridinderivater og nye indolderivater nyttige i behandlingen av 5-HT6 reseptorrelaterte forstyrrelser
FI905958A0 (fi) Foerfarande foer framstaellning av substituerade cyklohexanoler, som verkar pao det centrala nervsystemet.
NO942977L (no) Piperazin og piperidinderivater og anvendelse derav som antipsykotiske midler
EE03253B1 (et) (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised
DK0648778T3 (da) Nye 11-benzaldoximestradien-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
NO995006L (no) Nye forbindelser
NO953967L (no) Indolderivater som 5-HT1A og/eller 5-HT2 ligander
FI951454A0 (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
HUP9901820A2 (hu) 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
NO20022609D0 (no) Triazaspiro[5,5]undekan-derivater og medikamenter inneholdende slike som den aktive bestanddel
KR900700486A (ko) 신규한 벤조피리도 피페리딘, 피페리딜리덴 및 피페라진 화합물, 조성물, 제조방법 및 이용방법
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
NO20002787L (no) Nye forbindelser
NO883229L (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
CA2094703A1 (en) Substituted piperazines as central nervous system agents
NO971625L (no) Nye peptider med immunomodulatoriske effekter
BR0015540A (pt) Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
HK1046902A1 (zh) 新型哌嗪基烷基硫代嘧啶衍生物，包含該衍生物的藥物組合物以及製備該活性物質的方法
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister